Capricor Therapeutics Inc (CAPR)

[Volcano]

I like this part of CC
This is the strong case for accelerated approval definitely

As I said in my talk and I've been saying now for a few weeks' time is muscle what became very clear in the open label extension data is when they were off CAP-1002, they decline and as soon as they go back on CAP-1002, they get better. The placebo patients were on the steady course of decline similar to natural history for two straight years, the year on placebo and a year on gap and then as soon as they went on CAP-1002, the delay -- we saw the delay of the decline of the disease process by about 70%.